CB & CDx Europe

With increasing discoveries, clinical milestones, and partnership announcements, it is more critical than ever that the industry comes together to address the most pressing end-to-end challenges, ensuring the continued delivery of validated biomarkers and companion diagnostics to market.

With IVDR on the horizon and much of the industry looking to optimize the development of translatable biomarkers and streamline CDx development, schedule a meeting with us to discuss collaboration opportunities to overcome your portfolio planning challenges.